Advertisement
OtherArticle

Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling

Laura Schubert, Anh T. Le, Adriana Estrada-Bernal, Andrea E. Doak, Minjae Yoo, Sarah E. Ferrara, Andrew Goodspeed, Fumi Kinose, Uwe Rix, Aik-Choon Tan and Robert C. Doebele
Molecular Pharmacology April 1, 2021, MOLPHARM-AR-2020-000207; DOI: https://doi.org/10.1124/molpharm.120.000207
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherArticle

RET signaling in NSCLC

Laura Schubert, Anh T. Le, Adriana Estrada-Bernal, Andrea E. Doak, Minjae Yoo, Sarah E. Ferrara, Andrew Goodspeed, Fumi Kinose, Uwe Rix, Aik-Choon Tan and Robert C. Doebele
Molecular Pharmacology April 1, 2021, MOLPHARM-AR-2020-000207; DOI: https://doi.org/10.1124/molpharm.120.000207
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement